Loading stock…

Innoviva, Inc. (INVA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Innoviva, Inc.

INVAMarket cap $1.50BPrice $20.8

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Collects royalties on blockbuster respiratory drugs like Trelegy and Anoro while quietly building a portfolio of specialty pharma and biotech stakes. It's less a drugmaker, more a royalty machine cashing in on GSK's respiratory dominance.

In Bastion Portfolios?

52W Return+21%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+7%6

Revenue Forecast

Rev CAGR (1y)+10%6

Rev CAGR (3y)+7%5

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1-38%2

EPS Growth Y+2+6%5

EPS Growth Y+3-6%3

Quality

Margins

EBIT Margin38%9

Net Income Margin81%10

Free Cash Flow Margin43%10

Debt

Net Debt/EBITDA-1.310

Efficiency

ROE37%10

ROA24%10

Earnings Stability44

GEAR+VERY STRONG97

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)89

P/BV1.29

EV Multiples

EV/EBITDA Fwd310

EV/EBIT Fwd310

Yield

Free Cash Flow Yield12.6%10

Dividend Yieldna–

Momentum

Short term

1 month return-2%6

3 month return-6%4

YTD return+4%5

Mid term

Price vs 52wHigh83%6

1 year return+21%7

Long term

3 year return+56%6

5 year return+23%5

Risk Shield

Price Risk

Beta0.110

Volatility28%8

Free Cash Flow

Free Cash Flow Margin43%10

Free Cash Flow Yield12.6%10

Quality

ROCE12%7

Earnings Stability44

Net Debt/EBITDA-1.310

02Growth

Is it actually growing, and how fast?

INVAInnoviva

Revenue FY25$411M

GROWTH RATING↗

AVERAGE47 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+7%6

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-38%2

EPS growth, FY27E+6%5

EPS growth, FY28E-6%3

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

A mid-pack grower, ahead of 47% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 7%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

Earnings are set to fall even as revenue grows (EPS about -6%/yr vs revenue 7%/yr).

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%6

3-month return-6%4

YTD return+4%5

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return+21%7

3-year return+56%6

5-year return+23%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 21% over the past year, but 17% below its 52-week high. That is clearly ahead of the market.

WATCH

Average long-term results. Multi-year returns are middling (+56% over three years and +23% over five), roughly average for the market.

Returns sit at the market level over the past month (-2%), over three months (-6%) and so far this year (+4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Innoviva, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

INVAInnoviva

Revenue FY25$411M

GROWTH RATING↗

AVERAGE47 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+7%6

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-38%2

EPS growth, FY27E+6%5

EPS growth, FY28E-6%3

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

A mid-pack grower, ahead of 47% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 7%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

Earnings are set to fall even as revenue grows (EPS about -6%/yr vs revenue 7%/yr).

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%6

3-month return-6%4

YTD return+4%5

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return+21%7

3-year return+56%6

5-year return+23%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 21% over the past year, but 17% below its 52-week high. That is clearly ahead of the market.

WATCH

Average long-term results. Multi-year returns are middling (+56% over three years and +23% over five), roughly average for the market.

Returns sit at the market level over the past month (-2%), over three months (-6%) and so far this year (+4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Innoviva, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community